MYX mayne pharma group limited

Yes agree with you never had any time for this product , we paid...

  1. 1,467 Posts.
    lightbulb Created with Sketch. 289
    Yes agree with you never had any time for this product , we paid an exorbitant price for the rights to sell a newly developed product with nil proven earnings , shareholders stuck with 20 years exclusive right to sell in the States price paid based on extremely optimistic earning estimates / potential ( full potential ) product needing FDA approval + crazy high costs associated with this product such as establishing etc , etc this and running at a substantial loss ever since we took it on . Contraceptive pills been around since FDA first approve them in 1960 , how much longer are women going to continue to use something many thousands of women suffer severe side affects from ?. But now we're stuck with selling this product we paid though the nose for thanks to SR might be better to actually own Nexststellis IF Mithra's liquidators were to become the sellers provided Mithra go under of course , chance they might . Product worth whatever they can get for . Sold for so much of our money sunk into a product we don't own , liquidators will let it go for whatever ( zero attachment) think worth more to us than most other interested parties . Whats it worth ? guessing if liquidators were involved in the selling be a fraction of what Mithra thinks its worth that's for sure .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.03
Change
-0.170(3.27%)
Mkt cap ! $408.6M
Open High Low Value Volume
$5.20 $5.21 $5.03 $2.804M 555.6K

Buyers (Bids)

No. Vol. Price($)
2 14654 $5.03
 

Sellers (Offers)

Price($) Vol. No.
$5.14 3111 2
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.